Endometrial Cancer

P4, N=100, Not yet recruiting, GlaxoSmithKline

P=N/A, N=1010, Not yet recruiting, Natera, Inc. | Trial completion date: May 2034 --> Oct 2034 | Initiation date: May 2026 --> Oct 2026 | Trial primary completion date: May 2034 --> Oct 2034

Moreover, this thorough analysis can facilitate the exploration of potential disease-causing SNPs in the TFEB gene and assist in identifying effective drugs or pharmacological targets. Consequently, further experimental mutational research, genome-wide association studies, and clinical-based studies are essential to validate these findings.

Accumulating evidence highlights the potential role of FXYD3 as an emerging biomarker with relevance to diagnosis, prognosis, and therapeutics. This review provides an overview of FXYD3's role in cancer biology from translational relevance to its potential as a diagnostic, prognostic, and therapeutic target.

According to the pharmacogenomic analysis from GDSC2 dataset, tumor cells that express higher DNA2 are more sensitive to Tozasertib, and Daporinad. DNA2 is at the core of several interrelated modules, including flap processing, telomerase extension, and cell-cycle progression, according to the enrichment study. These findings have suggested DNA2 as a therapeutic vulnerability in cancer, a context-dependent biomarker with implications for treatment response, prognosis, and immunity.

P=N/A, N=48, Recruiting, University of Southern California | Not yet recruiting --> Recruiting | Initiation date: Dec 2026 --> Jun 2026

P1, N=24, Recruiting, Ruijin Hospital

Similarly, in endometrial cancer, CRISPR tools have elucidated mechanisms of hormonal resistance and facilitated the development of in vivo models via somatic gene editing. This review highlights recent advances in the application of CRISPR/Cas technology to gynecologic malignancies, discussing its potential as both a therapeutic and research platform while acknowledging current limitations and translational hurdles.

CDO1/CELF4 methylation analysis in cervical brushing samples is a highly accurate and reliable method for detecting EC and precursors, and no statistically significant difference in efficacy was observed compared to that of endometrial tissue tests. Its noninvasive nature can overcome significant diagnostic barriers, holding considerable promise as an effective triage tool for high-risk or symptomatic women, potentially revolutionizing early detection of EC and improving patient outcomes.

P2, N=240, Recruiting, Sheikh Shakhbout Medical City

The patient remains in remission with no evidence of disease. To our knowledge, this is the first reported case of ovarian SCLEC characterized by transcriptome-based molecular profiling.

P1/2, N=383, Active, not recruiting, MedImmune LLC | Trial completion date: Sep 2025 --> Jul 2027